Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thomas R. Valiquett"'
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 83:3169-3176
To assess the effects of troglitazone monotherapy on glycemic control in patients with type 2 diabetes mellitus, we carried out a 6-month, randomized, double-blind, placebo-controlled study in 24 hospital and outpatient clinics in the United States a
Autor:
Howard L. Foyt, Thomas R. Valiquett, Jean-François Yale, Janet K. Owens-Grillo, Randall W. Whitcomb, Mahmoud N. Ghazzi
Publikováno v:
Annals of Internal Medicine. 134:737
The thiazolidinediones are a new class of antidiabetes medication that enhances the actions of insulin in muscle, liver, and adipose tissue. Data have been lacking on their use in combination with both sulfonylurea and metformin among patients for wh
Autor:
Willa A. Hsueh, David E. Kelley, David Silver, Gerald I. Shulman, Thomas A. Buchanan, Jerrold M. Olefsky, Barry Gumbiner, Kenneth S. Polonsky, Gary W. Cline, John J. Nolan, Thomas R. Valiquett, Charles F. Burant, Silvio E. Inzucchi, David G. Maggs
Publikováno v:
Annals of Internal Medicine. 128:176
Background: Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus. The mechanism by which troglitazone exerts its effect on systemic glucose metabolism is unknown. Objective: To determine the effects of 6 months of tr